Valbonne, France, April 28, 2015 – TxCell SA (FR0010127662 – TXCL), a biotechnology company developing innovative, cost-effective, personalized T-cell immunotherapies using antigen specific regulatory ...
TxCell SA (Paris:TXCL) (FR0010127662 – TXCL), société de biotechnologies qui développe des immunothérapies cellulaires T personnalisées innovantes et économiquement compétitives, utilisant des ...
Plus, get the best of BroadwayWorld delivered to your inbox, and unlimited access to our editorial content across the globe. This is Forte's first studio album in three years and the first released on ...
TxCell SA has announced the appointment of Stéphane Boissel as Chief Executive Officer (CEO). In addition, Dr. Miguel Forte, previously SVP Clinical and Regulatory, is promoted to Chief Operating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results